Trevena

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing).

Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund

CHESTERBROOK, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a summary of activities at recent medical meetings, relating to OLINVYK® (oliceridine) injection, in several core therapeutic areas. Trevena attended the following medical congresses, which also featured presentations on OLINVYK® data:

OLINVYK® data selected as President's Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting

Trevena, Inc.'s (TRVN) CEO Carrie Bourdow on Q4 2021 Results - Earnings Call Transcript

Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and 100.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Trevena (TRVN) Reports Q4 Loss, Lags Revenue Estimates

CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing).

Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group

-- OLINVYK® utilization gaining traction in key target markets

Trevena Reports Fourth Quarter and Full Year 2021 Results

Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET

Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

CHESTERBROOK, Pa., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry Shin, Chief Financial Officer, will be participating in three January virtual investor and partnering conferences, with additional details below.

Trevena to Participate in the Upcoming January Conferences

Trevena (TRVN) advances TRV045 into clinical development as a potential treatment for diabetic neuropathic pain. Enrollment in the study is expected to begin in the first quarter of 2022.

Trevena (TRVN) to Begin Clinical Study on Pain Candidate

Trevena continues to struggle to get OLINVYK off the launch pad. COVID-19 headwinds are persisting, and it is having an impact on the company's ability to get through P&T committees. Trevena is building a body of evidence in OLINVYK's post-approval program. The company expects these additional studies should improve product adoption and potentially expand OLINVYK's label.

Trevena Offers An Enticing Risk-Reward At These Prices

3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers

Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and -84.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q3 2021 Results - Earnings Call Transcript

-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets

Trevena Reports Third Quarter 2021 Results

Patricia Drake appointed new Chief Commercial Officer Patricia Drake appointed new Chief Commercial Officer

Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team

Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET

Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021

Trevena (TRVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Trevena (TRVN) Q3 Earnings Expected to Decline

Posters highlight safety and tolerability data in two complex patient populations at higher risk for adverse events Posters highlight safety and tolerability data in two complex patient populations at higher risk for adverse events

Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021

Arbutus Biopharma

Adverum Biotechnologies

Kaleido Biosciences Inc

MannKind

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

Trevena Inc (NASDAQ: TRVN) has announced data from 30 patients enrolled in the proof-of-concept study of TRV027 in hospitalized COVID-19 patients.  The results showed that TRV027 was well-tolerated and provided initial evidence of its potential to improve biomarker and clinical endpoints associated with COVID-19.

Trevena Posts TRV027 Proof-of-Concept Study In Hospitalized COVID-19 Patients

-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality

Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients

CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer of Trevena, will present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit being held virtually from September 20th – 23rd.

Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit

PHILADELPHIA--(BUSINESS WIRE)--Imvax announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021.

Imvax Appoints John M. Limongelli as Chief Legal Officer

CHESTERBROOK, Penn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the acceptance of two abstracts at ANESTHESIOLOGY® 2021. Both abstracts highlight safety data from the OLINVYK (oliceridine) injection program. The meeting is sponsored by the American Society of Anesthesiologists and will be held on October 8th to 12th in San Diego, California.

Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021

-- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive function outcomes in postoperative patients

News for Trevena Stock (TRVN)